journal
MENU ▼
Read by QxMD icon Read
search

Annals of Hematology

journal
https://www.readbyqxmd.com/read/29785446/digital-droplet-pcr-based-absolute-quantification-of-pre-transplant-npm1-mutation-burden-predicts-relapse-in-acute-myeloid-leukemia-patients
#1
Marius Bill, Juliane Grimm, Madlen Jentzsch, Laura Kloss, Karoline Goldmann, Julia Schulz, Stefanie Beinicke, Janine Häntschel, Michael Cross, Vladan Vucinic, Wolfram Pönisch, Gerhard Behre, Georg-Nikolaus Franke, Thoralf Lange, Dietger Niederwieser, Sebastian Schwind
Allogeneic hematopoietic stem cell transplantation is an established consolidation therapy for patients with acute myeloid leukemia. However, relapse after transplantation remains a major clinical problem resulting in poor prognosis. Thus, detection of measurable ("minimal") residual disease to identify patients at high risk of relapse is essential. A feasible method to determine measurable residual disease may be digital droplet PCR (ddPCR) that allows absolute quantification with high sensitivity and specificity without the necessity of standard curves...
May 22, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29781040/autologous-stem-cell-transplantation-in-first-remission-is-associated-with-better-progression-free-survival-in-multiple-myeloma
#2
Mukul Aggarwal, Narendra Agrawal, Neha Yadav, Priyanka Verma, Rayaz Ahmed, Pallavi Mehta, Jyotsna Kapoor, Dinesh Bhurani
Autologous stem cell transplant (ASCT) is standard consolidation therapy in management of multiple myeloma (MM) patients. We reviewed records of all consecutive MM patients who underwent ASCT with high-dose melphalan at our center from year 2002 to 2016. A total of 141 ASCT were conducted (90 males and 51 females) with median age of 55 years (23-68 years). Median time from diagnosis to transplant was 7 months (3-79), with majority of patients underwent transplant in first remission, while 17 (12%) patients received transplant beyond first remission...
May 21, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29781039/sex-dependent-association-of-circulating-sex-steroids-and-pituitary-hormones-with-treatment-free-survival-in-chronic-lymphocytic-leukemia-patients
#3
Eric P Allain, Karin Venzl, Patrick Caron, Véronique Turcotte, David Simonyan, Michaela Gruber, Trang Le, Eric Lévesque, Chantal Guillemette, Katrina Vanura
Chronic lymphocytic leukemia (CLL) is not considered a hormone-regulated cancer although sex is a recognized risk factor with men more frequently diagnosed and developing progressive disease. We hypothesized that variable hormonal exposure may have a sexually dimorphic influence on treatment-free survival (TFS). In 156 CLL cases, we quantitatively profiled 29 circulating steroids (progesterone, adrenal precursors, androgens, estrogens, and catechol estrogens) as well as luteinizing hormone (LH) and follicle-stimulating hormone...
May 21, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29777278/low-platelet-count-as-risk-factor-for-infections-in-patients-with-primary-immune-thrombocytopenia-a-retrospective-evaluation
#4
Mingming Qu, Qiang Liu, Hong-Guo Zhao, Jun Peng, Heyu Ni, Ming Hou, A J Gerard Jansen
Infectious complications are common and sometimes life threatening in patients with immune thrombocytopenia (ITP), mainly due to the immune-suppressive therapy. Recent evidence suggests a potential role of platelets in the inflammation process. In this clinical study, we further investigated the role of thrombocytopenia on infections in patients with primary ITP. We retrospectively evaluated data from the recently published large randomized clinical trial of a cohort of 195 patients with primary ITP, who were randomized for prednisone or high-dose dexamethasone...
May 18, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29766236/ethnicity-specific-impact-of-hla-i-ii-genotypes-on-the-risk-of-inhibitor-development-data-from-korean-patients-with-severe-hemophilia-a
#5
Hyun-Young Kim, Jin-Hee Cho, Hee-Jung Kim, Hae-Sun Chung, Sun-Hee Kim, Ki-O Lee, Soo-Young Jung, Ki-Young Yoo, Hee-Jin Kim
Inhibitor development is the most serious complication in patients with hemophilia. We investigated association of HLA genotypes with inhibitor development in Korean patients with severe hemophilia A (HA). HLA genotyping was done in 100 patients with severe HA including 27 patients with inhibitors. The allele frequencies between inhibitor-positive and inhibitor-negative patients were compared. HLA class I alleles were not associated with the inhibitor status. In HLA class II, DRB1*15 [n = 100, odds ratio (OR) 0...
May 16, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29766235/localized-pain-causing-jak2-v617f-positive-myeloproliferation-with-normal-peripheral-blood-values
#6
LETTER
Magdalena M Gerlach, Christian Arranto, Stefan Dirnhofer, Alexandar Tzankov
No abstract text is available yet for this article.
May 16, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29766234/the-severe-cytokine-release-syndrome-in-phase-i-trials-of-cd19-car-t-cell-therapy-a-systematic-review
#7
REVIEW
Zhen Jin, Rufang Xiang, Kai Qing, Xiaoyang Li, Yunxiang Zhang, Lining Wang, Hongming Zhu, Yuanfei Mao, Zizhen Xu, Junmin Li
CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive results in treating acute lymphoblastic leukemia (B-ALL), chronic lymphoblastic leukemia (B-CLL), and B-cell non-Hodgkin lymphoma (B-NHL) over the past few years. Meanwhile, the cytokine release syndrome (CRS), which could be moderate or even life-threatening, has emerged as the most significant adverse effect in the clinical course of this novel targeting immunotherapy. In this systematic review, we analyzed the incidence of severe CRS in 19 clinical trials selected from studies published between 2010 and 2017...
May 15, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29756171/real-world-data-on-len-dex-combination-at-second-line-therapy-of-multiple-myeloma-treatment-at-biochemical-relapse-is-a-significant-prognostic-factor-for-progression-free-survival
#8
Eirini Katroditou, Marie-Christine Kyrtsonis, Sosana Delimpasi, Despoina Kyriakou, Argiris Symeonidis, Emmanouil Spanoudakis, Georgios Vasilopoulos, Achilles Anagnostopoulos, Anna Kioumi, Panagiotis Zikos, Anthi Aktypi, Evangelos Briasoulis, Aikaterini Megalakaki, Panayiotis Repousis, Ioannis Adamopoulos, Dimitrios Gogos, Maria Kotsopoulou, Vassiliki Pappa, Eleni Papadaki, Despoina Fotiou, Eftychia Nikolaou, Evlambia Giannopoulou, Eleftheria Hatzimichael, Nikolaos Giannakoulas, Vassiliki Douka, Kyriaki Kokoviadou, Despoina Timotheatou, Evangelos Terpos
We evaluated progression-free survival (PFS) rate of patients treated with lenalidomide/dexamethasone (Len/Dex), the efficacy of the combination, and the prognostic significance of treatment at biochemical vs. clinical relapse on PFS in 207 consecutive myeloma patients treated with Len/Dex in second line, according to routine clinical practice in Greece. First-line treatment included bortezomib-based (63.3%) or immunomodulatory drug-based (34.8%) therapies; 25% of patients underwent autologous stem cell transplantation...
May 13, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29754273/drug-induced-liver-failure-due-to-rivaroxaban
#9
LETTER
Matthew Peverelle, Khashayar Asadi, Marie Sinclair
No abstract text is available yet for this article.
May 12, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29754272/hypertransaminasemia-revealing-a-clinically-silent-muscular-dystrophy-in-a-child-with-sickle-cell-disease
#10
LETTER
Naouel Guirat Dhouib, Monia Ben Khaled, Monia Ouederni, Habib Besbes, Fethi Mellouli, Mohamed Bejaoui
No abstract text is available yet for this article.
May 12, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29754271/reduced-dose-epoch-r-chemotherapy-for-elderly-patients-with-advanced-stage-diffuse-large-b-cell-lymphoma
#11
Wen-Hao Zhang, Gao-Yang Li, Yu-Jie Ma, Zhi-Chao Li, Yang Zhu, Jun Chang, Si-Guo Hao, Rong Tao
The standard treatment in elderly patients with diffuse large B cell lymphoma (DLBCL) has not yet been finely established. We investigated the efficacy and safety of rituximab with a reduced-dose of EPOCH chemotherapy in elderly patients who had advanced DLBCL with high IPI scores. The dose of 70% EPOCH was given to patients aged 75 to 79 years, and dose of 50% to patients aged over 80 years. Thirty-one patients with a median age of 79 years (range 75-86 years) were enrolled. Patients received a median of 6 cycle's chemotherapy...
May 12, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29752545/routine-surveillance-imaging-in-follicular-lymphoma
#12
LETTER
Marc Sorigue, Juan-Manuel Sancho
No abstract text is available yet for this article.
May 11, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29750316/elevated-soluble-cd23-level-indicates-increased-risk-of-b-cell-non-hodgkin-s-lymphomas-evidence-from-a-meta-analysis
#13
REVIEW
Yi-Shu Huang, Xiang Zhou, Zhi-Fang Yang, Zheng-Tao Lv
The aim of the present study was to determine whether circulating soluble CD23 (sCD23) was associated with B cells non-Hodgkin's lymphomas (B-NHL). PubMed, EMBASE, and ISI Web of Science were extensively searched without language restriction. Data was extracted in a standardized data collection sheet after two reviewers scanned studies independently. The association between sCD23 and NHL was indicated as odds ratio (OR) along with its related 95% confidence interval (95% CI). Meta-analysis was conducted via RevMan 5...
May 11, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29740685/efficacy-of-decitabine-as-hemoglobin-f-inducer-in-hbe-%C3%AE-thalassemia
#14
Siddhesh Arun Kalantri, Rudra Ray, Arnab Chattopadhyay, Sunistha Bhattacharjee, Ankita Biswas, Maitreyee Bhattacharyya
To study safety, efficacy (hemoglobin and hemoglobin F percentage increment in non-transfusion-dependent patients and decrease in transfusion frequency in transfusion-dependent patients), and determinants of response of decitabine in patients with HbE/β-thalassemia. Thirty patients of HbE/β-thalassemia (age > 18 years) were enrolled. Both transfusion-dependent (TDT) and non-transfusion-dependent (NTDT) patients were included after obtaining informed consent. Participants received 0.2 mg/kg of 5-aza-2'-deoxycytidine (decitabine) subcutaneously on 2 consecutive days a week for at least 12 weeks...
May 9, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29740684/severe-anemia-after-trans-catheter-arterial-chemoembolization-an-unusual-presentation-of-hemoglobin-zurich
#15
LETTER
Tanja Böhme, Michael Medinger, Claudia Suenderhauf, Oliver Speer, Markus Schmugge, Jakob Passweg, Adrian Bachofner
No abstract text is available yet for this article.
May 8, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29740683/chronic-lymphocytic-leukemia-international-prognostic-index-cll-ipi-in-patients-receiving-chemoimmuno-or-targeted-therapy-a-systematic-review-and-meta-analysis
#16
LETTER
Stefano Molica, Diana Giannarelli, Rosanna Mirabelli, Luciano Levato, Tait D Shanafelt
No abstract text is available yet for this article.
May 8, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29736587/a-higher-percentage-of-cells-with-13q-deletion-predicts-worse-outcome-in-chinese-patients-with-chronic-lymphocytic-leukemia-carrying-isolated-13q-deletion
#17
Yuqing Miao, Yi Miao, Ke Shi, Qian Sun, Si-Shu Zhao, Yi Xia, Shu-Chao Qin, Hai-Rong Qiu, Hui Yang, Hao Xu, Hua-Yuan Zhu, Jia-Zhu Wu, Wei Wu, Lei Cao, Li Wang, Lei Fan, Wei Xu, Jian-Yong Li
Previous studies showed that, in chronic lymphocytic leukemia (CLL) patients with isolated 13q deletion (13q-), those carrying higher percentage of leukemic cells with 13q- had more aggressive diseases. However, the prognostic value of the percentage of leukemic cells with 13q- in Chinese CLL patients with isolated 13q- remained to be determined. Using interphase fluorescence in situ hybridization (FISH), we identified 82 patients (25.4%) with isolated 13q deletion from a cohort of 323 untreated CLL patients...
May 7, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29732477/effectiveness-of-rituximab-containing-treatment-regimens-in-idiopathic-multicentric-castleman-disease
#18
Yujun Dong, Lu Zhang, Lin Nong, Lihong Wang, Zeyin Liang, Daobin Zhou, David C Fajgenbaum, Hanyun Ren, Jian Li
Human herpes virus type 8 (HHV-8)-negative, idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disease often involving constitutional symptoms, cytopenias, and multiple organ system dysfunction. In China, the majority of MCD cases are HHV-8 negative. Given that siltuximab, the only FDA-approved treatment for iMCD is not available in China; rituximab- and cyclophosphamide-containing regimens are often used in the treatment of Chinese iMCD patients. To evaluate the efficacy of rituximab in this rare and heterogeneous disease, clinical and pathological data from 27 cases of iMCD were retrospectively analyzed from two large medical centers in China...
May 7, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29728736/splenic-marginal-zone-lymphoma-with-a-de-novo-t-8-14-q24-q32-and-a-prolymphocytoid-evolution-responsive-to-rituximab-bendamustine
#19
LETTER
Greta Scapinello, Marco Pizzi, Stefania Vio, Mitja Nabergoj, Andrea Visentin, Annalisa Martines, Laura Bonaldi, Livio Trentin, Gianpietro Semenzato, Francesco Piazza
No abstract text is available yet for this article.
May 4, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29728735/would-you-think-of-histiocytic-sarcoma-in-this-fine-needle-aspiration
#20
LETTER
Cristiano Claudino Oliveira, Júlia Thalita Queiroz Rocha, Gustavo Fernandes Silva, Bruna Biglia, Rafael Dezen Gaiolla, Ligia Niero-Melo, Maria Aparecida Custódio Domingues
No abstract text is available yet for this article.
May 4, 2018: Annals of Hematology
journal
journal
30731
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"